相关实验视频
通过HipA介导的多药耐药性及其通过HipB的中和的分子机制
Maria A Schumacher1, Kevin M Piro, Weijun Xu
1Department of Biochemistry and Molecular Biology, University of Texas, M. D. Anderson Cancer Center, Unit 1000, Houston, TX 77030, USA. maschuma@mdanderson.org
概括
由持久细胞驱动的细菌多药耐受性是一个主要的抗生素挑战. 研究人员阐明了关键的持久性因子HipA及其抑制剂HipB的结构和功能,揭示了抗生素耐药性的机制.
科学领域:
- 微生物学 微生物学
- 分子生物学分子生物学
- 结构生物学 结构生物学
背景情况:
- 细菌的多种药物耐受性阻碍了抗生素的疗效.
- 持久细胞,一个休眠的亚群,负责这种耐受性.
- 大肠杆菌中的HipA蛋白是细菌持久性的关键因素.
研究的目的:
- 为了阐明HipA的激酶活性的结构基础.
- 了解 HipB 中和 HipA 的机制.
- 揭示控制HipA介导的持久性和HipB调节的分子相互作用.
主要方法:
- 使用X射线晶体学来确定HipA和HipA-HipB-DNA复合体的结构.
- 进行了生物化学测试,以评估HipA的激酶活性和HipB的抑制功能.
主要成果:
- HipA表现出一种真核细胞的氨酸/氨酸激酶类折叠,并酸化转化因子EF-Tu,这表明它在细胞静止中发挥了作用.
- 这种HipA-HipB-DNA复杂结构揭示了HipB的DNA结合机制,显著的DNA曲,以及新的HipA-DNA相互作用.
- 狄米瑞克HipB通过隔离和构造性无活化抑制HipA的激酶活性.
结论:
- 这些发现提供了对HipA介导细菌持久性分子机制的见解.
- 这项研究揭示了HipB如何抵消HipA的活动,为抗生素开发提供了潜在的目标.
- 了解这些相互作用对于克服抗生素耐药性至关重要.
相关概念视频
Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...